iSpecimen Inc. (NASDAQ:ISPC) Sees Large Increase in Short Interest

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a significant increase in short interest during the month of May. As of May 29th, there was short interest totaling 241,056 shares, an increase of 113.6% from the May 14th total of 112,840 shares. Based on an average daily volume of 386,118 shares, the days-to-cover ratio is presently 0.6 days. Approximately 19.1% of the shares of the company are short sold.

iSpecimen Stock Performance

ISPC stock remained flat at $2.75 during trading on Friday. The company had a trading volume of 108,522 shares, compared to its average volume of 235,423. The stock’s 50-day moving average is $4.39 and its 200-day moving average is $9.94. The firm has a market capitalization of $3.96 million, a P/E ratio of -0.04 and a beta of 1.62. iSpecimen has a 52 week low of $2.54 and a 52 week high of $127.20.

iSpecimen (NASDAQ:ISPC) last announced its quarterly earnings results on Friday, May 15th. The company reported ($6.66) earnings per share for the quarter. The company had revenue of $0.16 million for the quarter. iSpecimen had a negative net margin of 1,080.16% and a negative return on equity of 584.65%.

Wall Street Analyst Weigh In

ISPC has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of iSpecimen in a research report on Tuesday, April 21st. Wall Street Zen upgraded iSpecimen to a “sell” rating in a research report on Saturday, May 2nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, iSpecimen has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iSpecimen stock. Scientech Research LLC acquired a new stake in iSpecimen Inc. (NASDAQ:ISPC) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 29,488 shares of the company’s stock, valued at approximately $38,000. Scientech Research LLC owned 0.30% of iSpecimen at the end of the most recent quarter. Hedge funds and other institutional investors own 13.62% of the company’s stock.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.